Alpha Teknova, Inc. (TKNO)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
$6.96+1.09%
Close 2026-09-09 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
Intact: The reason to own it still holds.
Alpha Teknova is growing revenue toward $42-44 million in 2026. Gross profit rose from $3.24M to $3.78M in recent quarters, showing margin improvement. Management reaffirmed a positive free cash flow outlook near $10 million. The company supports key biotech sectors like vaccines and gene therapy.
The company remains unprofitable with negative EPS expected through 2027. Free cash flow is still weak and below prior year levels. Revenue growth may slow as competition and market risks persist.
The price is about 20% above our fair value near $4.50. Analysts expect roughly 13% revenue growth, which aligns with management guidance. Our view is cautious given ongoing losses and modest growth estimates.
Breaks if: free cash flow remains negative or below $5 million in FY26
Breaks if: gross profit falls below $3.2 million per quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. TKNO is currently loss-making but has shown some signs of recovery and management stability, making it a name to watch in the healthcare sector.
The market seems to be pricing in a durable premium for TKNO, reflecting a 31% expectations gap compared to peers. However, this premium may not be justified given the company's current loss-making status and elevated risk factors.
Management is focused on achieving their revenue guidance of $45-47 million for 2026, which appears to be on track. However, the company is still facing challenges with free cash outflow and the early-stage launch of their AI-powered product.
The long-term thesis hinges on TKNO's ability to maintain its revenue guidance and manage cash flow effectively. Additionally, the performance of sector bellwethers and overall economic conditions, such as job growth, will be crucial in determining the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company achieved its 2026 revenue guidance of $45-47 million. Record revenue and raised guidance support growth objectives. Recent earnings performance indicates strong revenue growth.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Increase gross profit margins through higher revenue and operational efficiencies to enhance profitability.
Breaks if: annual revenue falls below $40 million in FY26
Continue to grow revenue to meet the raised 2026 guidance range of $45-47 million.
Stated as a priority in 2 of last 2 quarters. Revenue grew from $11.1 million in 2026-Q1 to $12.2 million in 2026-Q2 (+10%). Management raised full-year 2026 revenue guidance from $42-44 million to $45-47 million, reflecting delivery and positive trajectory.
“CFO: 'We are therefore raising our 2026 revenue guidance to $45-47 million.'”
“CFO: 'We therefore reiterate our 2026 revenue guidance of $42-44 million.'”
In the next 1-3 years, TKNO's performance will depend on management execution and external market conditions. Not investment advice.